TNF Pharma begins phase 2b clinical trial to evaluate oral TNF-alpha inhibitor drug candidate isomyosamine: Baltimore Thursday, February 27, 2025, 18:00 Hrs [IST] TNF Pharmaceutic ...

6 Isomyosamine is a novel plant alkaloid small molecule shown to regulate the immuno-metabolic system through the modulation of numerous pro-inflammatory cytokines including TNF-alpha (TNF-α), an ...

The relationship between food allergies and chronic illness represents one of the most significant yet underappreciated ...

The traditional understanding of inflammation focused primarily on its acute manifestations, the classic signs of redness, ...

The interplay between cortisol, inflammation, and disease underscores the need for effective stress management to enhance ...

Use of GLP-1 receptor agonists for obesity was associated with a reduced risk of primary open-angle glaucoma (POAG) and ...

Q2 2025 Earnings Conference Call February 26, 2025 5:00 PM ETCompany ParticipantsSilviu Itescu - Chief Executive ...

Quercetin is a powerful natural compound with significant immune-boosting and anti-inflammatory properties. Whether you’re ...

IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer Patient enrollment in Phase ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Phase 3 Ovarian Cancer Trial to Initiate in March 2025 Imunon, Inc. (NASDAQ:IMNN) is continuing preparations to conduct a Phase 3 clinical trial ...

Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC; Announcement of initial data from 12-month evaluable ...

While osteoporosis is more common in women, obesity-related bone density loss is a growing concern for men, leading to early-onset osteoporosis and even spinal deformities., Health News - Times Now ...